問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei City Hospital Songde Branch (在職)

Division of Psychiatry

Taipei City Hospital (在職)

Division of Psychiatry

Linkou Chang Gung Medical Foundation (在職)

Division of Psychiatry

更新時間：2023-09-19

林式穀
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林式穀

List

42Cases

2012-05-01 - 2013-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2008-12-01 - 2011-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-01-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-07-07 - 2013-06-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-09-01 - 2016-02-28

Phase III

Long-term Extension Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    Schizophrenia

  • Test Drug

    SM-13496

Participate Sites
8Sites

Terminated8Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2012-08-01 - 2015-08-31

Phase III

Randomized, Double-blind, Parallel- group, Placebo-controlled, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    schizophrenia

  • Test Drug

    SM-13496

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2013-12-18 - 2015-10-31

Phase III

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients with Major Depressive Disorder

  • Condition/Disease

    Major depressive disorder

  • Test Drug

    ASC-01

Participate Sites
12Sites

Terminated12Sites

藍先元
China Medical University Hospital

Division of Psychiatry

2006-07-20 - 2007-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-05-04 - 2020-12-31

Phase II

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia

  • Condition/Disease

    Patients with established Schizophrenia (as per DSM-5) who are clinically stable

  • Test Drug

    BI 425809

Participate Sites
4Sites

Terminated4Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2008-10-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB